 | |
| Clinical data | |
|---|---|
| Other names | SY-004 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C28H37N3O3S3 |
| Molar mass | 559.80 g·mol−1 |
Globalagliatin (SY-004) is a glucokinase activator developed by Yabao Pharmaceutical Group for type 2 diabetes. [1] [2] [3]
References
- ^ Zhao, Yuqing; Xie, Lijun; Zhang, Hongwen; Zhou, Sufeng; Liu, Yun; Chen, Juan; Wang, Lu; Wang, Libin; Zhuo, Lang; Wang, Yarong; Ou, Ning; Shao, Feng (February 2022). "Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of SY-004, a Glucokinase Activator, in Healthy Chinese Adults: A Randomized, Phase Ia, Single-Ascending Dose Study". Clinical Therapeutics. 44 (2): 269–281. doi: 10.1016/j.clinthera.2021.12.009. PMID 35093240. S2CID 246416557.
- ^ Zheng, Shuai; Shao, Feng; Ding, Yu; Fu, Zhenzhen; Fu, Qi; Ding, Sijia; Xie, Lijun; Chen, Juan; Zhou, Sufeng; Zhang, Hongwen; Zhou, Hongwen; Chen, Yang; Sun, Caixia; Zhu, Jing; Zheng, Xuqin; Yang, Tao (December 2020). "Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study". Clinical Drug Investigation. 40 (12): 1155–1166. doi: 10.1007/s40261-020-00971-x. PMID 33125674. S2CID 225983121.
- ^ Yang, Wenjia; Wu, Han; Cai, Xiaoling; Lin, Chu; Jiao, Ruoyang; Ji, Linong (8 May 2023). "Evaluation of efficacy and safety of glucokinase activators—a systematic review and meta-analysis". Frontiers in Endocrinology. 14. doi: 10.3389/fendo.2023.1175198. PMC 10200948. PMID 37223016.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
|
| |
| Clinical data | |
|---|---|
| Other names | SY-004 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C28H37N3O3S3 |
| Molar mass | 559.80 g·mol−1 |
Globalagliatin (SY-004) is a glucokinase activator developed by Yabao Pharmaceutical Group for type 2 diabetes. [1] [2] [3]
References
- ^ Zhao, Yuqing; Xie, Lijun; Zhang, Hongwen; Zhou, Sufeng; Liu, Yun; Chen, Juan; Wang, Lu; Wang, Libin; Zhuo, Lang; Wang, Yarong; Ou, Ning; Shao, Feng (February 2022). "Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of SY-004, a Glucokinase Activator, in Healthy Chinese Adults: A Randomized, Phase Ia, Single-Ascending Dose Study". Clinical Therapeutics. 44 (2): 269–281. doi: 10.1016/j.clinthera.2021.12.009. PMID 35093240. S2CID 246416557.
- ^ Zheng, Shuai; Shao, Feng; Ding, Yu; Fu, Zhenzhen; Fu, Qi; Ding, Sijia; Xie, Lijun; Chen, Juan; Zhou, Sufeng; Zhang, Hongwen; Zhou, Hongwen; Chen, Yang; Sun, Caixia; Zhu, Jing; Zheng, Xuqin; Yang, Tao (December 2020). "Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study". Clinical Drug Investigation. 40 (12): 1155–1166. doi: 10.1007/s40261-020-00971-x. PMID 33125674. S2CID 225983121.
- ^ Yang, Wenjia; Wu, Han; Cai, Xiaoling; Lin, Chu; Jiao, Ruoyang; Ji, Linong (8 May 2023). "Evaluation of efficacy and safety of glucokinase activators—a systematic review and meta-analysis". Frontiers in Endocrinology. 14. doi: 10.3389/fendo.2023.1175198. PMC 10200948. PMID 37223016.
|
| This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |